Scientists at the University of Illinois Urbana-Champaign revealed oPool+ display, a high-throughput technology capable of synthesizing and assessing hundreds of antibodies in parallel against viral antigens. This platform integrates oligo pool synthesis with mRNA display to rapidly characterize antibody specificity, compressing weeks or months of work into days. The study demonstrated screening over 300 influenza hemagglutinin-specific antibodies across multiple variants, conducting thousands of binding tests with minimal hands-on time. This advancement promises to transform antibody-driven therapeutic discovery and accelerate immunology research.